James McGibbon of The Almac Group recently sat down with Rare Disease Report to discuss the challenges that small biotech companies face when launching an orphan drug on a global scale.
The European based company now has an office in the U.S. to help companies of all sizes market their orphan drug products. For more information, visit [ Ссылка ]

свернуть